-
1
-
-
15444370728
-
Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas
-
Park JM, Terabe M, Sakai Y, et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005;10(7):4228-4236
-
(2005)
J Immunol
, vol.10
, Issue.7
, pp. 4228-4236
-
-
Park, J.M.1
Terabe, M.2
Sakai, Y.3
-
2
-
-
40949112441
-
Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine
-
Park JM, Terabe M, Steel JC, et al. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res 2008;68(6):1979-1987
-
(2008)
Cancer Res
, vol.68
, Issue.6
, pp. 1979-1987
-
-
Park, J.M.1
Terabe, M.2
Steel, J.C.3
-
3
-
-
0030749292
-
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
-
Gjertsen MK, Bjorheim J, Saeterdal I, et al. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72(5):784-790
-
(1997)
Int J Cancer
, vol.72
, Issue.5
, pp. 784-790
-
-
Gjertsen, M.K.1
Bjorheim, J.2
Saeterdal, I.3
-
4
-
-
0032433127
-
The central role of CD4+ T cells in the antitumor immune response
-
Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998;188(12):2357-2368
-
(1998)
J Exp Med
, vol.188
, Issue.12
, pp. 2357-2368
-
-
Hung, K.1
Hayashi, R.2
Lafond-Walker, A.3
-
5
-
-
65249127501
-
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine
-
•• The first reported use, to our knowledge, of Ad-WT1 for vaccine immunotherapy in vivo
-
Osada T, Woo CY, McKinney M, et al. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res 2009;15(8):2789-2796 •• The first reported use, to our knowledge, of Ad-WT1 for vaccine immunotherapy in vivo.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.8
, pp. 2789-2796
-
-
Osada, T.1
Woo, C.Y.2
McKinney, M.3
-
6
-
-
0025605969
-
Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence
-
Rauscher FJ III, Morris JF, Tournay OE, et al. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990;250(4985):1259-1262
-
(1990)
Science
, vol.250
, Issue.4985
, pp. 1259-1262
-
-
Rauscher III, F.J.1
Morris, J.F.2
Tournay, O.E.3
-
7
-
-
0026669131
-
Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
-
Drummond IA, Madden SL, Rohwer-Nutter P, et al. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992;257(5070):674-678
-
(1992)
Science
, vol.257
, Issue.5070
, pp. 674-678
-
-
Drummond, I.A.1
Madden, S.L.2
Rohwer-Nutter, P.3
-
8
-
-
0027278677
-
Increased expression of the insulin-like growth factor i receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product
-
Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 1993;90(12):5828-5832
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, Issue.12
, pp. 5828-5832
-
-
Werner, H.1
Re, G.G.2
Drummond, I.A.3
-
9
-
-
0027384536
-
Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus
-
Harrington MA, Konicek B, Song A, et al. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993;268(28):21271-21275
-
(1993)
J Biol Chem
, vol.268
, Issue.28
, pp. 21271-21275
-
-
Harrington, M.A.1
Konicek, B.2
Song, A.3
-
10
-
-
0025291908
-
The candidate Wilms' tumour gene is involved in genitourinary development
-
Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990;346(6280):194-197
-
(1990)
Nature
, vol.346
, Issue.6280
, pp. 194-197
-
-
Pritchard-Jones, K.1
Fleming, S.2
Davidson, D.3
-
11
-
-
0029102956
-
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis
-
Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14(19):4662-4675
-
(1995)
EMBO J
, vol.14
, Issue.19
, pp. 4662-4675
-
-
Englert, C.1
Hou, X.2
Maheswaran, S.3
-
12
-
-
0035827923
-
WT1 proteins: Functions in growth and differentiation
-
Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001;273(2):141-161
-
(2001)
Gene
, vol.273
, Issue.2
, pp. 141-161
-
-
Scharnhorst, V.1
Van Der Eb, A.J.2
Jochemsen, A.G.3
-
13
-
-
0025099787
-
Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
-
Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60(3):509-520
-
(1990)
Cell
, vol.60
, Issue.3
, pp. 509-520
-
-
Call, K.M.1
Glaser, T.2
Ito, C.Y.3
-
14
-
-
0032992295
-
Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth
-
Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90(2):194-204
-
(1999)
Jpn J Cancer Res
, vol.90
, Issue.2
, pp. 194-204
-
-
Oji, Y.1
Ogawa, H.2
Tamaki, H.3
-
15
-
-
0026751042
-
Expression of the Wilms' tumor gene (WT1) in human leukemias
-
Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6(5):405-409
-
(1992)
Leukemia
, vol.6
, Issue.5
, pp. 405-409
-
-
Miwa, H.1
Beran, M.2
Saunders, G.F.3
-
16
-
-
0030737629
-
High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
-
Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90(3):1217-1225
-
(1997)
Blood
, vol.90
, Issue.3
, pp. 1217-1225
-
-
Bergmann, L.1
Miething, C.2
Maurer, U.3
-
17
-
-
33745067420
-
WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: An immunohistochemical study
-
Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, et al. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 2006;6:90
-
(2006)
BMC Cancer
, vol.6
, pp. 90
-
-
Netinatsunthorn, W.1
Hanprasertpong, J.2
Dechsukhum, C.3
-
18
-
-
0036091359
-
High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients
-
Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8(5):1167-1171 (Pubitemid 34517654)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.5
, pp. 1167-1171
-
-
Miyoshi, Y.1
Ando, A.2
Egawa, C.3
Taguchi, T.4
Tamaki, Y.5
Tamaki, H.6
Sugiyama, H.7
Noguchi, S.8
-
19
-
-
40249116647
-
Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis
-
Sera T, Hiasa Y, Mashiba T, et al. Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer 2008;44(4):600-608
-
(2008)
Eur J Cancer
, vol.44
, Issue.4
, pp. 600-608
-
-
Sera, T.1
Hiasa, Y.2
Mashiba, T.3
-
20
-
-
44749084527
-
WT1 peptide vaccine for the treatment of cancer
-
Oka Y, Tsuboi A, Oji Y, et al. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008;20(2):211-220
-
(2008)
Curr Opin Immunol
, vol.20
, Issue.2
, pp. 211-220
-
-
Oka, Y.1
Tsuboi, A.2
Oji, Y.3
-
21
-
-
33947322028
-
Immunotherapeutic targeting of Wilms' tumor protein
-
Hutchings Y, Osada T, Woo CY, et al. Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther 2007;9(1):62-69
-
(2007)
Curr Opin Mol Ther
, vol.9
, Issue.1
, pp. 62-69
-
-
Hutchings, Y.1
Osada, T.2
Woo, C.Y.3
-
22
-
-
0034112824
-
Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
-
Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000;51(2):99-107 (Pubitemid 30150969)
-
(2000)
Immunogenetics
, vol.51
, Issue.2
, pp. 99-107
-
-
Oka, Y.1
Elisseeva, O.A.2
Tsuboi, A.3
Ogawa, H.4
Tamaki, H.5
Li, H.6
Oji, Y.7
Kim, E.H.8
Soma, T.9
Asada, M.10
Ueda, K.11
Maruya, E.12
Saji, H.13
Kishimoto, T.14
Udaka, K.15
Sugiyama, H.16
-
23
-
-
0034176750
-
Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
-
Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95(7):2198-2203
-
(2000)
Blood
, vol.95
, Issue.7
, pp. 2198-2203
-
-
Gao, L.1
Bellantuono, I.2
Elsasser, A.3
-
24
-
-
0033966369
-
HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
-
Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95(1):286-293
-
(2000)
Blood
, vol.95
, Issue.1
, pp. 286-293
-
-
Ohminami, H.1
Yasukawa, M.2
Fujita, S.3
-
25
-
-
61349095387
-
Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue
-
Al Qudaihi G, Lehe C, Negash M, et al. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue. Leuk Lymphoma 2009;50(2):260-269
-
(2009)
Leuk Lymphoma
, vol.50
, Issue.2
, pp. 260-269
-
-
Al Qudaihi, G.1
Lehe, C.2
Negash, M.3
-
26
-
-
33750291285
-
Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein
-
Pinilla-Ibarz J, May RJ, Korontsvit T, et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006;20(11):2025-2033
-
(2006)
Leukemia
, vol.20
, Issue.11
, pp. 2025-2033
-
-
Pinilla-Ibarz, J.1
May, R.J.2
Korontsvit, T.3
-
27
-
-
23744460167
-
Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner
-
Guo Y, Niiya H, Azuma T, et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood 2005;106(4):1415-1418
-
(2005)
Blood
, vol.106
, Issue.4
, pp. 1415-1418
-
-
Guo, Y.1
Niiya, H.2
Azuma, T.3
-
28
-
-
33645300343
-
Defining MHC class II T helper epitopes for WT1 tumor antigen
-
Kobayashi H, Nagato T, Aoki N, et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006;55(7):850-860
-
(2006)
Cancer Immunol Immunother
, vol.55
, Issue.7
, pp. 850-860
-
-
Kobayashi, H.1
Nagato, T.2
Aoki, N.3
-
29
-
-
0036566202
-
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
-
Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99(9):3272-3279
-
(2002)
Blood
, vol.99
, Issue.9
, pp. 3272-3279
-
-
Elisseeva, O.A.1
Oka, Y.2
Tsuboi, A.3
-
30
-
-
0034651735
-
Cancer immunotherapy targeting Wilms' tumor gene WT1 product
-
• One of the first reports detailing WT1 immunotherapy in vivo for WT1 expressing tumors
-
Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000;164(4):1873-1880 • One of the first reports detailing WT1 immunotherapy in vivo for WT1 expressing tumors.
-
(2000)
J Immunol
, vol.164
, Issue.4
, pp. 1873-1880
-
-
Oka, Y.1
Udaka, K.2
Tsuboi, A.3
-
31
-
-
0034663331
-
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
-
Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000;96(4):1480-1489
-
(2000)
Blood
, vol.96
, Issue.4
, pp. 1480-1489
-
-
Gaiger, A.1
Reese, V.2
Disis, M.L.3
Cheever, M.A.4
-
32
-
-
0033916081
-
Cytotoxic T-Lymphocyte responses elicited to wilms' tumor gene WT1 product by DNA vaccination
-
DOI 10.1023/A:1006637529995
-
Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000;20(3):195-202 (Pubitemid 30485880)
-
(2000)
Journal of Clinical Immunology
, vol.20
, Issue.3
, pp. 195-202
-
-
Tsuboi, A.1
Oka, Y.2
Ogawa, H.3
Elisseeva, O.A.4
Li, H.5
Kawasaki, K.6
Aozasa, K.7
Kishimoto, T.8
Udaka, K.9
Sugiyama, H.10
-
33
-
-
3042720809
-
WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone
-
Nakajima H, Kawasaki K, Oka Y, et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004;53(7):617-624
-
(2004)
Cancer Immunol Immunother
, vol.53
, Issue.7
, pp. 617-624
-
-
Nakajima, H.1
Kawasaki, K.2
Oka, Y.3
-
34
-
-
53449089933
-
DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance
-
Chaise C, Buchan SL, Rice J, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008;112(7):2956-2964
-
(2008)
Blood
, vol.112
, Issue.7
, pp. 2956-2964
-
-
Chaise, C.1
Buchan, S.L.2
Rice, J.3
-
35
-
-
4644289323
-
Induction of WT1 (Wilms' tumor gene)- specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
-
• The first major, Phase I clinical trial, to our knowledge, evaluating WT1 peptide based vaccine in patients with both hematological and solid malignancies
-
Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)- specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101(38):13885-13890 • The first major, Phase I clinical trial, to our knowledge, evaluating WT1 peptide based vaccine in patients with both hematological and solid malignancies.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, Issue.38
, pp. 13885-13890
-
-
Oka, Y.1
Tsuboi, A.2
Taguchi, T.3
-
36
-
-
38049188363
-
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
-
Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111(1):236-242
-
(2008)
Blood
, vol.111
, Issue.1
, pp. 236-242
-
-
Rezvani, K.1
Yong, A.S.2
Mielke, S.3
-
37
-
-
69249220181
-
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
-
Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113(26):6541-6548
-
(2009)
Blood
, vol.113
, Issue.26
, pp. 6541-6548
-
-
Keilholz, U.1
Letsch, A.2
Busse, A.3
-
38
-
-
33745686444
-
A Phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: Safety assessment based on the phase i data
-
Morita S, Oka Y, Tsuboi A, et al. A Phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006;36(4):231-236
-
(2006)
Jpn J Clin Oncol
, vol.36
, Issue.4
, pp. 231-236
-
-
Morita, S.1
Oka, Y.2
Tsuboi, A.3
-
39
-
-
34249106425
-
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma
-
Iiyama T, Udaka K, Takeda S, et al. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007;51(5):519-530
-
(2007)
Microbiol Immunol
, vol.51
, Issue.5
, pp. 519-530
-
-
Iiyama, T.1
Udaka, K.2
Takeda, S.3
-
40
-
-
43249090418
-
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
-
Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008;108(5):963-971
-
(2008)
J Neurosurg
, vol.108
, Issue.5
, pp. 963-971
-
-
Izumoto, S.1
Tsuboi, A.2
Oka, Y.3
-
41
-
-
33750823731
-
Recent clinical progress in virus-based therapies for cancer
-
Woo CY, Osada T, Clay TM, et al. Recent clinical progress in virus-based therapies for cancer. Expert Opin Biol Ther 2006;6(11):1123-1134
-
(2006)
Expert Opin Biol Ther
, vol.6
, Issue.11
, pp. 1123-1134
-
-
Woo, C.Y.1
Osada, T.2
Clay, T.M.3
-
42
-
-
54849406164
-
Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus
-
Vujanovic L, Whiteside TL, Potter DM, et al. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother 2009;58(1):121-133
-
(2009)
Cancer Immunol Immunother
, vol.58
, Issue.1
, pp. 121-133
-
-
Vujanovic, L.1
Whiteside, T.L.2
Potter, D.M.3
-
43
-
-
0031962522
-
High efficiency adenovirus-mediated gene transfer to human dendritic cells
-
Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998;91(2):392-398
-
(1998)
Blood
, vol.91
, Issue.2
, pp. 392-398
-
-
Dietz, A.B.1
Vuk-Pavlovic, S.2
-
44
-
-
0029560716
-
Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector
-
Juillard V, Villefroy P, Godfrin D, et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995;25(12):3467-3473
-
(1995)
Eur J Immunol
, vol.25
, Issue.12
, pp. 3467-3473
-
-
Juillard, V.1
Villefroy, P.2
Godfrin, D.3
-
45
-
-
0029936764
-
Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
-
Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996;2(5):545-550
-
(1996)
Nat Med
, vol.2
, Issue.5
, pp. 545-550
-
-
Tripathy, S.K.1
Black, H.B.2
Goldwasser, E.3
Leiden, J.M.4
-
46
-
-
27544510429
-
Adenovirus as vehicle for anticancer genetic immunotherapy
-
Gallo P, Dharmapuri S, Cipriani B, Monaci P. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther 2005;12(Suppl 1):S84-91
-
(2005)
Gene Ther
, vol.12
, Issue.SUPPL. 1
-
-
Gallo, P.1
Dharmapuri, S.2
Cipriani, B.3
Monaci, P.4
-
47
-
-
57349167467
-
The current status of adenovirus-based cancer gene therapy
-
Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008;25(4):462-466
-
(2008)
Mol Cells
, vol.25
, Issue.4
, pp. 462-466
-
-
Shirakawa, T.1
-
48
-
-
70450164178
-
Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors
-
Seregin SS, Amalfitano A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin Biol Ther 2009;9(12):1521-1531
-
(2009)
Expert Opin Biol Ther
, vol.9
, Issue.12
, pp. 1521-1531
-
-
Seregin, S.S.1
Amalfitano, A.2
-
49
-
-
0033056699
-
Frequency and stability of chromosomal integration of adenovirus vectors
-
Harui A, Suzuki S, Kochanek S, Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999;73(7):6141-6146
-
(1999)
J Virol
, vol.73
, Issue.7
, pp. 6141-6146
-
-
Harui, A.1
Suzuki, S.2
Kochanek, S.3
Mitani, K.4
-
50
-
-
56649105122
-
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial
-
Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-1893
-
(2008)
Lancet
, vol.372
, Issue.9653
, pp. 1881-1893
-
-
Buchbinder, S.P.1
Mehrotra, D.V.2
Duerr, A.3
-
51
-
-
0028328261
-
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
-
Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91(10):4407-4411
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, Issue.10
, pp. 4407-4411
-
-
Yang, Y.1
Nunes, F.A.2
Berencsi, K.3
-
53
-
-
68949205787
-
Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity
-
Osada T, Yang XY, Hartman ZC, et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009;16(9):673-682
-
(2009)
Cancer Gene Ther
, vol.16
, Issue.9
, pp. 673-682
-
-
Osada, T.1
Yang, X.Y.2
Hartman, Z.C.3
-
54
-
-
33645086129
-
Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors
-
Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 2006;16(3):241-259
-
(2006)
Cell Res
, vol.16
, Issue.3
, pp. 241-259
-
-
Xia, D.1
Moyana, T.2
Xiang, J.3
-
55
-
-
8644282802
-
Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector
-
Gallo P, Dharmapuri S, Nuzzo M, et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005;113(1):67-77
-
(2005)
Int J Cancer
, vol.113
, Issue.1
, pp. 67-77
-
-
Gallo, P.1
Dharmapuri, S.2
Nuzzo, M.3
-
56
-
-
33748867886
-
HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination
-
Chan T, Sami A, El-Gayed A, et al. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther 2006;13(19):1391-1402
-
(2006)
Gene Ther
, vol.13
, Issue.19
, pp. 1391-1402
-
-
Chan, T.1
Sami, A.2
El-Gayed, A.3
-
57
-
-
77951881263
-
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo
-
[Epub Ahead of Print]
-
Morse MA, Wei J, Hartman Z, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer 2009 [Epub Ahead of Print]
-
(2009)
Int J Cancer
-
-
Morse, M.A.1
Wei, J.2
Hartman, Z.3
-
58
-
-
25844449779
-
Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies
-
Essand M. Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies. Acta Oncol 2005;44(6):610-627
-
(2005)
Acta Oncol
, vol.44
, Issue.6
, pp. 610-627
-
-
Essand, M.1
-
59
-
-
0035892365
-
Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors
-
Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001;94(6):842-849
-
(2001)
Int J Cancer
, vol.94
, Issue.6
, pp. 842-849
-
-
Elzey, B.D.1
Siemens, D.R.2
Ratliff, T.L.3
Lubaroff, D.M.4
-
60
-
-
67049155480
-
Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer
-
Kim S, Lee JB, Lee GK, Chang J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 2009;69(9):938-948
-
(2009)
Prostate
, vol.69
, Issue.9
, pp. 938-948
-
-
Kim, S.1
Lee, J.B.2
Lee, G.K.3
Chang, J.4
-
61
-
-
1242293633
-
Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin
-
Lane C, Leitch J, Tan X, et al. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 2004;64(4):1509-1514
-
(2004)
Cancer Res
, vol.64
, Issue.4
, pp. 1509-1514
-
-
Lane, C.1
Leitch, J.2
Tan, X.3
-
62
-
-
2142644402
-
CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine
-
Leitch J, Fraser K, Lane C, et al. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol 2004;172(9):5200-5205
-
(2004)
J Immunol
, vol.172
, Issue.9
, pp. 5200-5205
-
-
Leitch, J.1
Fraser, K.2
Lane, C.3
-
63
-
-
0034893581
-
Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism
-
Steitz J, Bruck J, Knop J, Tuting T. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism. Gene Ther 2001;8(16):1255-1263
-
(2001)
Gene Ther
, vol.8
, Issue.16
, pp. 1255-1263
-
-
Steitz, J.1
Bruck, J.2
Knop, J.3
Tuting, T.4
-
64
-
-
0034095604
-
Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: Implications for cancer vaccines
-
Wan Y, Bramson J, Pilon A, et al. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 2000;60(12):3247-3253
-
(2000)
Cancer Res
, vol.60
, Issue.12
, pp. 3247-3253
-
-
Wan, Y.1
Bramson, J.2
Pilon, A.3
-
65
-
-
0032539190
-
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
-
Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90(24):1894-1900
-
(1998)
J Natl Cancer Inst
, vol.90
, Issue.24
, pp. 1894-1900
-
-
Rosenberg, S.A.1
Zhai, Y.2
Yang, J.C.3
-
66
-
-
0033948976
-
Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A Phase I/II clinical trial
-
Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur Urol 2000;38(2):208-217
-
(2000)
Eur Urol
, vol.38
, Issue.2
, pp. 208-217
-
-
Mincheff, M.1
Tchakarov, S.2
Zoubak, S.3
-
67
-
-
33744479760
-
Phase i Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer
-
Nemunaitis J, Meyers T, Senzer N, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006;13(6):1185-1191
-
(2006)
Mol Ther
, vol.13
, Issue.6
, pp. 1185-1191
-
-
Nemunaitis, J.1
Meyers, T.2
Senzer, N.3
-
68
-
-
41149164895
-
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
-
Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31(3):294-309
-
(2008)
J Immunother
, vol.31
, Issue.3
, pp. 294-309
-
-
Butterfield, L.H.1
Comin-Anduix, B.2
Vujanovic, L.3
-
69
-
-
0032052293
-
Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product
-
Bardeesy N, Pelletier J. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. Nucleic Acids Res 1998;26(7):1784-1792
-
(1998)
Nucleic Acids Res
, vol.26
, Issue.7
, pp. 1784-1792
-
-
Bardeesy, N.1
Pelletier, J.2
-
70
-
-
4344616068
-
Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy
-
Kast WM, Levitsky H, Marincola FM. Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med 2004;2(1):20
-
(2004)
J Transl Med
, vol.2
, Issue.1
, pp. 20
-
-
Kast, W.M.1
Levitsky, H.2
Marincola, F.M.3
-
71
-
-
33644879983
-
Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide
-
Oh ST, Kim CH, Park MY, et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006;24(15):2860-2868
-
(2006)
Vaccine
, vol.24
, Issue.15
, pp. 2860-2868
-
-
Oh, S.T.1
Kim, C.H.2
Park, M.Y.3
-
72
-
-
51049083609
-
The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: Implications for immunotherapy
-
Lehe C, Ghebeh H, Al-Sulaiman A, et al. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res 2008;68(15):6350-6359
-
(2008)
Cancer Res
, vol.68
, Issue.15
, pp. 6350-6359
-
-
Lehe, C.1
Ghebeh, H.2
Al-Sulaiman, A.3
-
73
-
-
33644869748
-
CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand
-
Salucci V, Mennuni C, Calvaruso F, et al. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 2006;63(1):35-41
-
(2006)
Scand J Immunol
, vol.63
, Issue.1
, pp. 35-41
-
-
Salucci, V.1
Mennuni, C.2
Calvaruso, F.3
-
74
-
-
70350568201
-
A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo
-
Thacker EE, Nakayama M, Smith BF, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009;27(50):7116-7124
-
(2009)
Vaccine
, vol.27
, Issue.50
, pp. 7116-7124
-
-
Thacker, E.E.1
Nakayama, M.2
Smith, B.F.3
-
75
-
-
61349182678
-
Will changing the face of WT1 make it more attractive to T cells?
-
Kline J. Will changing the face of WT1 make it more attractive to T cells? Leuk Lymphoma 2009;50(2):156-157
-
(2009)
Leuk Lymphoma
, vol.50
, Issue.2
, pp. 156-157
-
-
Kline, J.1
|